uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Show others and affiliations
2015 (English)In: Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, E-ISSN 1432-0843, Vol. 75, no 4, 791-803 p.Article in journal (Refereed) Published
Abstract [en]

To characterize the population pharmacokinetics of bevacizumab, its binding properties to VEGF(165) and the effect of demographic data and VEGF-A polymorphisms on the interplay between bevacizumab serum pharmacokinetics and VEGF(165) serum concentrations in patients with colorectal cancer stage IV. Bevacizumab and VEGF(165) data were collected from 19 adult patients with metastatic colorectal cancer enrolled in an observational clinical study. Bevacizumab was administered with one of the following combinations: 5-FU/Leucovorin/Irinotecan, 5-FU/Leucovorin/Oxaliplatin, Capecitabine/Irinotecan at doses ranging from 5 to 10 mg/kg every 2 or 3 weeks. Data analysis was performed using nonlinear mixed-effects modeling implemented in NONMEM 7.3. A target-mediated drug disposition model adequately described bevacizumab concentration changes over time and its binding characteristics to VEGF(165). The estimated clearance of bevacizumab was 0.18 L/day, the free VEGF(165) levels at baseline were 212 ng/L, and the elimination rate constant of free VEGF(165) was 0.401 day(-1). Body weight was allometrically included in all PK parameters. The final model adequately described the pre- and post-dose concentrations of total bevacizumab and free VEGF(165) in patients with colorectal cancer. Model parameters were consistent with those previously reported for patients with solid tumors. Correlations between the binding affinity of bevacizumab and the VEGF-2578C/A and VEGF-634G/C polymorphisms were noticed.

Place, publisher, year, edition, pages
2015. Vol. 75, no 4, 791-803 p.
Keyword [en]
Bevacizumab, VEGF, Population modeling, VEGF polymorphisms, Colorectal cancer
National Category
Pharmaceutical Sciences Cancer and Oncology
URN: urn:nbn:se:uu:diva-258818DOI: 10.1007/s00280-015-2701-3ISI: 000351549100015PubMedID: 25687989OAI: oai:DiVA.org:uu-258818DiVA: diva2:842940
Swedish Cancer Society
Available from: 2015-07-23 Created: 2015-07-20 Last updated: 2015-07-23Bibliographically approved

Open Access in DiVA

fulltext(713 kB)107 downloads
File information
File name FULLTEXT01.pdfFile size 713 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Schindler, EmilieFriberg, Lena E.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Cancer Chemotherapy and Pharmacology
Pharmaceutical SciencesCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 107 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 333 hits
ReferencesLink to record
Permanent link

Direct link